NCT04430738 2026-02-24Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen Inc.Phase 2 Active not recruiting40 enrolled 67 charts